If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baqsimi™ (glucagon) nasal powder
3mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Baqsimi is contraindicated in people with
pheochromocytoma because of the risk of substantial increase in blood pressure
insulinoma because of the risk of hypoglycemia, and
known hypersensitivity to glucagon or to any of the excipients in Baqsimi.1
Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.1
Enclosed Prescribing Information
BAQSIMI™ (glucagon) nasal powder, for intranasal use, Lilly
1. Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
Baqsimi = Baqsimi™ (glucagon) nasal powder
Date of Last Review: November 16, 2020
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST